Showing 221-230 of 334 grants
| Title | Institution | Researcher | Program | Duration | Total Award Amount |
|---|---|---|---|---|---|
| Targeting ER cargo proteins for beta cell protection against cellular stress and autoimmunity | Indiana Biosciences Research Institute | Erica Cai | Cures | 01-September-2023 to 31-August-2026 | $499.934,12 |
| Development of a safe and effective islet-targeted nanoplasmid based CXCL12 gene delivery system using cationic nanobubble-mediated sonotransfection to restore and immune protect the residual beta cell mass in T1D | Massachusetts General Hospital | Mark Poznansky | Cures | 01-April-2023 to 31-March-2026 | $777.168,00 |
| The master regulator transcription factor, Zbtb20, defines and controls a regulatory T cell subset that controls tissue inflammation. | Rutgers Biomedical and Health Sciences | Derek Sant’Angelo | Cures | 01-March-2023 to 28-February-2027 | $935.026,00 |
| Modulate beta cell proliferation and immunogenicity via aptamer-decorated lipid nanoparticles | University of Miami | Paolo Serafini | Cures | 01-April-2023 to 31-March-2026 | $894.602,00 |
| Multicolor cellular immunoimaging of response to transplanted islet cells | Michigan State University | Bryan Smith | Cures | 01-June-2023 to 31-May-2026 | $750.000,00 |
| Spotlight-AQ 2 Center RCT | Children's Mercy Hospital | Cintya Schweisberger | Improving Lives | 01-September-2023 to 31-August-2026 | $710.434,16 |
| A Cure for Type 1 Diabetes | University of Massachusetts Medical School | David Harlan | Cures | 01-October-2022 to 30-September-2025 | $12.998.645,40 |
| JDRF-IQVIA Adult T1D Detection | IQVIA, Inc. | Nadejda Leavitt | Cures | 01-October-2022 to 31-August-2025 | $953.780,00 |
| Enabling studies to advance intra-lymph node depots as a durable antigen-specific immunotherapy for T1D | University of Maryland | Christopher Jewell | Cures | 01-February-2023 to 31-January-2026 | $989.997,00 |
| Engineered Nanoparticles for Beta Cell-Targeted Therapeutics | The University of Chicago | Raghavendra Mirmira | Cures | 01-April-2023 to 31-March-2026 | $897.822,00 |